247582-73-6

Basic information

• Product Name: 2-ETHOXY-5-(4-ETHYLPIPERAZINE-1-SULFONYL]NICOTINIC ACID
• Synonyms: 2-ETHOXY-5-(4-ETHYLPIPERAZINE-1-SULFONYL]NICOTINIC ACID
• CAS NO: 247582-73-6
• Molecular Formula: C14H21N3O5S
• Molecular Weight: 343.4
• Mol File: 247582-73-6.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 519.1±60.0 °C(Predicted)
• Appearance: /
• Density: 1.322±0.06 g/cm3(Predicted)
• PKA: 3.06±0.10(Predicted)
• CAS DataBase Reference: 2-ETHOXY-5-(4-ETHYLPIPERAZINE-1-SULFONYL]NICOTINIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-ETHOXY-5-(4-ETHYLPIPERAZINE-1-SULFONYL]NICOTINIC ACID(247582-73-6)
• EPA Substance Registry System: 2-ETHOXY-5-(4-ETHYLPIPERAZINE-1-SULFONYL]NICOTINIC ACID(247582-73-6)

Safety Data

• Hazardous Substances Data: 247582-73-6(Hazardous Substances Data)

Usage

General Description

2-ETHOXY-5-(4-ETHYLPIPERAZINE-1-SULFONYL)NICOTINIC ACID, also known as E5448, is a chemical compound belonging to the class of nicotinic acid derivatives. It is a selective antagonist of the purinergic P2 receptor and has potential applications in the treatment of various inflammatory and autoimmune diseases. E5448 has been studied for its ability to inhibit the release of various inflammatory mediators and has shown promise in preclinical models of rheumatoid arthritis, inflammatory bowel disease, and other autoimmune conditions. It is currently being investigated for its potential therapeutic effects in clinical trials.

Upstream product

• 247582-68-9 2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic Acid Ethyl Ester 
• 5308-25-8 4-ethylpiperazine 
• 141-52-6 sodium ethanolate 
• 504-29-0 2-aminopyridine 
• 247582-63-4 pyridine-3-bromo-5-(4-ethylpiperazin-1-ylsulphonyl)-2-chloride 
• 264920-27-6 3-Bromo-2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine 
• 16250-08-1 pyridine-2-amino-5-sulphonic acid 
• 216394-05-7 5-bromo-6-chloropyridine-3-sulfonyl chloride 
• 247582-62-3 2-Amino-3-bromopyridine-5-sulphonic Acid 
• 334708-08-6 Ethyl 2-chloro-5-(4-ethyl-1-piperazinylsulfonyl) nicotinoate 
• 609-71-2 2-hydroxy-3-carboxypyridine 
• 334708-05-3 2-hydroxy-5-sulfonicotinic acid 
• 334708-07-5 ethyl 2-chloro-5-(chlorosulfonyl)nicotinate 

Relevant articles and documents

The process development of a scaleable route to the PDE5 inhibitor UK-357,903

A case history is outlined for the development of a scaleable route to the drug candidate UK-357,903. Despite the partial structural similarities to those of sildenafil (Viagra), the introduction of the central pyridine moiety within UK-357,903 had a significant impact on the commercial process. In particular, the triply activated 2-alkoxypyridyl moiety of UK-357,903 is much more susceptible to nucleophilic attack than the 2-ethoxyphenyl moiety of sildenafil, necessitating the development of new chemistry. Particular items of note are (i) the new six-step route to the advanced 2-ethoxy-5-(4-ethylpiperazinylsulfonyl)nicotinic acid intermediate and the subsequent telescoping to a two-pot process, (ii) the telescoping of the two steps from N-[3-carbamoyl-5-ethyl-1-(2-pyridylmethyl)-1H-pyrazol-4-yl]-2-ethoxy-5- (4-ethyl-1-piperazinylsulfonyl)nicotin-amide to UK-357,903 to a single step, with the additional use of a hydroxide trapping agent to give an ambient pressure process yielding clinical quality product, and (iii) the introduction of process modifications to allow for the use of teratogenic 2-methoxyethanol, as both reagent and solvent, in the penultimate process step.

Pyrazolopyrimidine derivatives

The present invention provides a compound of formula (I): where Q is a group of formula: These compounds inhibit cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDEs). More notably, the compounds are potent and selective inhibitors of the type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases and have utility therefore in a variety of therapeutic areas. In particular, the present compounds are of value for the curative or prophylactic treatment of mammalian sexual disorders.

Novel process for the preparation of pyrazolopyrimidinones

There is provided a process for the production a compound of general formula I: 1wherein A, R1, R2, R3 and R4 have meanings given in the description, which process comprises the dehydrogenation of a compound of general formula II, 2